Natural and engineered nucleic acids as tools to explore biology

Nature

Volumn 432, Issue 7019, 2004, Pages 838-845

  Breaker, Ronald R ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPOLYMERS; CHEMICAL REACTIONS; DNA; FUNCTIONS; GENES; RNA;

BIOLOGICAL SYSTEMS; DOUBLE-HELICAL STRUCTURES; MOLECULAR ENGINEERS; THERAPEUTICS;

NUCLEIC ACIDS;

DEOXYRIBOZYME; DNA; NATURAL PRODUCT; NUCLEIC ACID; PROTEIN DERIVATIVE; RIBOZYME; RNA;

BIOLOGY;

ALLOSTERISM; BIOENGINEERING; CATALYSIS; CATALYST; COMPLEX FORMATION; CORRELATION ANALYSIS; CYTOLOGY; DNA DEGRADATION; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE CONTROL; GENE SWITCHING; HUMAN; LIGAND BINDING; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA DEGRADATION; STRUCTURE ANALYSIS;

ALLOSTERIC REGULATION; ANIMALS; BASE SEQUENCE; DNA, CATALYTIC; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; HUMANS; NUCLEIC ACIDS; RNA, CATALYTIC;

HARNESS;

EID: 11144330098     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03195     Document Type: Review

References (115)

1. Kolkman, J. A. & Stemmer, P. C. Directed evolution of proteins by exon shuffling. Nature Biotechnol. 19, 423-428 (2001).
2. Zhao, H., Chockalingam, K. & Chen, Z. Directed evolution of enzymes and pathways for industrial biocatalysis. Curr. Opin. Biotechnol. 13, 104-110 (2002).
3. Joyce, G. F. Directed evolution of nucleic acid enzymes. Annu. Rev. Biochem. 73, 791-836 (2004).
4. Wilson, D. S. & Szostak, J. W. In vitro selection of functional nucleic acids. Annu. Rev. Biochem. 68, 611-647 (1999).
5. McPherson, M. J. & Møller S. G. PCR (Springer, New York, 2000).
6. Dykxhoorn, D. M., Novina, C. D. & Sharp, P. A. Killing the messenger: short RNAs that silence gene expression. Nature Rev. Mol. Cell Biol. 23, 1961-1967 (2003).
7. Novina, C. D. & Sharp, P. A. The RNAi revolution. Nature 430, 161-164 (2004).
8. Khudyakov, Y. E. & Fields, H. A. Artificial DNA: methods and applications (CRC, Boca Raton, Florida, 2002).
9. Muller, S., Wolf, J. & Ivanov, S. A. Current strategies for the synthesis of RNA. Curr. Org. Syn. 1, 293-307 (2004).
10. Milligan, J. F. & Uhlenbeck, O. C. Synthesis of small RNAs using T7 RNA polymerase. Methods Enzymol. 180, 51-62 (1989).
11. Watson, J. D. & Crick, F. H. C. Molecular structure of nucleic acids. Nature 171, 737-738 (1953).
12. Uhlenbeck, O. C. A small catalytic oligoribonucleotide. Nature 328, 596-600 (1989).
13. Nissen, P., Hansen, J., Ban, N., Moore, P. B. & Steitz, T. A. The structural basis of ribosome activity in peptide bond synthesis. Science 289, 920-930 (2000).
14. Steitz, T. A. & Moore, P. B. RNA, the first macromolecular catalyst: the ribosome is a ribozyme. Trends Biochem. Sci. 28, 411-418 (2003).
15. Stein, C. A. & Krieg, A. M. Applied Antisense Oligonucleotide Technology. (eds Stein, C. A. & Krieg, A. M.) (Wiley, New York, 1998).
16. Crooke, S. T. Progress in antisense technology, Annu. Rev. Med. 55, 61-95 (2004).
17. Reese, C. B. & Yan, H. B. Solution phase synthesis of ISIS 2922 (Vitravene) by the modified H-phosphonate approach. J. Chem. Soc. Perkins Trans. 1, 2619-2633 (2002).
18. Holmlund, J. T. Applying antisense technology. Ann. NY Acad. Sci. 1002, 244-251 (2003).
19. Meister, G. & Tuschl, T. Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343-349 (2004).
20. Eaton, B. E. & Pieken, W. A. Ribonucleosides and RNA. Annu. Rev. Biochem. 64, 837-863 (1995).
21. Sarafianos, S. G., Hughes, S. H. & Arnold, E. Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs. Int. J. Biochem. Cell Biol. 36, 1706-1715 (2004).
22. Gold, L., Polisky, B., Uhlenbeck, O. & Yarus, M. Diversity of oligonucleotide functions. Annu. Rev. Biochem. 64, 763-797 (1995).
23. Osborne, S. E. & Ellington, A. D. Nucleic acid selection and the challenge of combinatorial chemistry. Chem. Rev. 97, 349-370 (1997).
24. Koizumi, M., Soukup, G. A., Kerr, J. N. Q. & Breaker, R. R. Allosteric selection of ribozymes that respond to the second messengers cGMP and cAMP. Nature Struct. Biol. 6, 1062-1071 (1999).
25. Soukup, G. A., DeRose, E. C., Koizumi, M. & Breaker, R. R. Generating new ligand-binding RNAs by affinity maturation and disintegration of allosteric ribozymes. RNA 7, 524-536 (2001).
26. Jayasena, S. D. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. 9, 1628-1650 (1999).
27. Brockstedt, U., Uzarowska, A., Montpetit, A., Pfau, W. & Labuda, D. In vitro evolution of RNA aptamers recognizing carcinogenic aromatic amines. Biochem. Biophys. Res. Commun. 313, 1004-1008 (2004).
28. Saver, N. M. et al. Structural determinants of conformationally selective, prion-binding aptamers. J. Biol. Chem. 279, 13102-13109 (2004).
29. Romig, T. S., Bell, C. & Drolet, D. W. Aptamer affinity chromatography: combinatorial chemistry applied to protein purification. J. Chromatogr. B. Biomed. Sci. Appl. 731, 275-284 (1999).
30. Deng, Q., German, I., Buchanan, D. & Kennedy, R. T. Retention and separation of adenosine and analogues by affinity chromatography with an aptamer stationary phase. Anal. Chem. 73, 5415-5421 (2001).
31. Hermann, T. & Patel, D. J. Adaptive recognition by nucleic acid aptamers. Science 287, 820-825 (2000).
32. Hamaguchi, N., Ellington, A. & Stanton, M. Aptamer beacons for the direct detection of proteins. Anal. Biochem. 294, 126-131 (2001).
33. McCauley, T. G., Hamaguchi, N. & Stanton, M. Aptamer-based biosensor arrays for detection and quantification of biological macromolecules. Anal. Biochem. 319, 244-250 (2003).
34. Jhaveri, S., Rajendran, M. & Ellington, A. D. In vitro selection of signaling aptamers. Nature Biotechnol. 18, 1293-1297 (2000).
35. Peracchi, A. Prospects for antiviral ribozymes and deoxyribozymes. Rev. Med. Virol. 14, 47-64 (2004).
36. Opalinska, J. B. & Gewirtz, A. M. Nucleic acid therapeutics: basic principles and recent applications. Nature Rev. Drug Disc. 1, 503-514 (2002).
37. Lin, Y., Qiu, Q., Gill, C. & Jayasena, S. D. Modified RNA sequence pools for in vitro selection. Nucleic Acids Res. 22, 5229-5234 (1994).
38. Beaudry, A., DeFoe, J., Zinnen, S., Burgin, A. & Beigelman, L. In vitro selection of a novel nuclease-resistant RNA phosphodiesterase. Chem. Biol. 7, 323-334 (2000).
39. Famulok, M. & Verma, S. In vivo-applied functional RNAs as tools in proteomics and genomics research. Trends Biotechnol. 20, 462-466 (2002).
40. Toolmé, J.-J., Di Primo, C. & Boucard, D. Regulating eukaryotic gene expression with aptamers. FEBS Lett. 567, 55-62 (2004).
41. Homann, M. & Göringer, H. U. Uptake and intracellular transport of RNA aptamers in African trypanosomes suggests therapeutic 'piggy-back' approach. Bioorg. Med. Chem. 9, 2571-2580 (2001).
42. Vater, A. & Klussmann, S. Towards third-generation aptamers: spiegelmers and their therapeutic prospects. Curr. Opin. Drug Disc. Devel. 6, 253-261 (2003).
43. Eulberg, D. & Klussmann, S. Spiegelmeers: biostable aptamers. Chembiochen. 4, 979-983 (2003).
44. Nolte, A., Klussmann, S., Bald, R., Erdmann, V. A. & Furste J. P. Mirror-design of L-oligonucleotide ligands binding to L-arginine. Nature Biotechnol. 14, 1112-1115 (1996).
45. Cox, J. C. & Ellington, A. D. Automated selection of anti-protein aptamers. Bioorg. Med. Chem. 9, 2525-2531 (2001).
46. Sooter, L. J. et al. Towards automated nucleic acid enzyme selection. Biol. Chem. 9, 1327-1334 (2001).
47. Cox, I. C. et al. Automated acquisition of aptamer sequences. Comb. Chem. High Throughput Screen. 4, 289-299 (2002).
48. Cox, J. C. et al. Automated selection of aptamers against protein targets translated in vitro: from gene to aptamer. Nucleic Acids Res. 30, e108 (2002).
49. Csaky, K. Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: promises and pitfalls. Ophthalmology 110, 879-881 (2003).
50. Boncler, M. A., Koziolkiewicz, M. & Watala, C. Aptamer inhibits degradation of platelet proteolytically activatable receptor, PAR-1, by thrombin. Thromb. Res. 104, 215-222 (2002).
51. Rusconi, C. P. et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419, 90-94 (2002).
52. Nissen, P., Hansen, J., Ban, N., Moore, P. B. & Steitz, T. A. The structural basis of ribosomal activity in peptide bond synthesis. Science 289, 920-930 (2000).
53. Hansen, J. L. et al. The structures of four macrolide antibiotics bound to the large ribosomal subunit. Mol. Cell 10, 117-128 (2002).
54. Hansen, J. L., Moore, P. B. & Steitz, T. A. Structures of five antibiotics bound at the peptidyl transferase center of the large ribosomal subunit. J. Mol. Biol. 330, 1061-1075 (2003).
55. Schlünzen, F. et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in cubacteria. Nature 413, 814-821 (2001).
56. Bagheri, S. & Kashani-Sabet, M. Ribozymes in the age of molecular therapeutics. Curr. Mol. Med. 4, 489-506 (2004).
57. Kawa, D., Wang, J., Yuan, Y., & Liu, F. Inhibition of viral gene expression by human ribonuclease P. RNA 4, 1397-1406 (1998).
58. Plehn-Dujowich, D. & Altman, S. Effective inhibition of influenza production in cultured cells by external guide sequences and ribonuclease P. Proc. Natl Acad. Sci. USA 95, 7327-7331 (1998).
59. Rangarajan, S., Raj, M. L. S., Hernandez, J. M., Grotewold, E. & Gopalan, V. RNase P as a tool for disruption of gene expression in maize cells. Biomed. J. 380, 611-616 (2004).
60. Byun, J., Lan, N., Long, M. & Sullenger, B. A. Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes. RNA 9, 1254-1263 (2003).
61. Sullenger, B. A. & Gilboa, E. Emerging clinical applications of RNA. Nature 418, 252-258 (2002).
62. Perutka, J., Wang, W. J., Goerlitz, D. & Lambowitz, A. M. Use of computer-designed group II introns to disrupt Escherichia coli DExH/D-box protein and DNA helicase genes. J. Mol. Biol. 336, 421-439 (2004).
63. Jarvis, T. C. et al. Ribozymes as tools for therapeutic target validation in arthritis. J. Immunol. 165, 493-498 (2000).
64. Wilson, C. & Szostak, J. W. In vitro evolution of a self-alky lating ribozyme. Nature 374, 777-782 (1995).
65. Unrau, P. J. & Bartel, D. P. RNA-catalysed nucleotide synthesis. Nature 395, 260-263 (1998).
66. Baskerville, S. & Bartel, D. P. A ribozyme that ligates RNA to protein. Proc. Natl Acad. Sci. USA 99, 9154-9159 (2002).
67. Tang, J. & Breaker, R. R. Structural diversity of self-cleaving ribozymes. Proc. Natl Acad. Sci. USA 97, 5784-5789 (2000).
68. Lazarev, D., Puskarz, I. & Breaker, R. R. Substrate specificity and reaction kinetics of an X-motif ribozyme. RNA 9, 688-697 (2003).
69. Emilsson, G. M. & Breaker, R. R. Deoxyribozymes: new activities and new applications. Cell. Mol. Life Sci. 59, 596-607 (2002).
70. Santoro, S. W. & Joyce, G. F. A general purpose RNA-cleaving DNA enzyme. Proc. Natl Acad. Sci. USA 94, 4262-4266 (1997).
71. Santoro, S. W. & Joyce, G. F. Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry 37, 13330-13342 (1998).
72. Santiago, F. S. et al. New DNA enzyme targeting Erg-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nature Med. 5, 1264-1269 (1999).
73. Santiago, F. S. & Khachigian, L. M. Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis. J. Mol. Med. 79, 695-706 (2001).
74. Li, Y. & Breaker, R. R. Phosphorylating DNA with DNA. Proc. Natl Acad. Sci. USA 96, 2746-2751 (1999).
75. Wang, W., Billen, L. P. & Li, Y. Sequence diversity, metal specificity, and catalytic proficiency of metal-dependent phosphorylating DNA enzymes. Chem. Biol. 9, 507-517 (2002).
76. Sreedhara, A., Li, Y. F. & Breaker, R. R. Ligating DNA with DNA. J. Am. Chem. Soc. 126, 3454-3460 (2004).
77. Uhlenbeck, O. C. Keeping RNA happy. RNA 1, 4-6 (1995).
78. Jiang, F., Kumar, R. A., Jones, R. A. & Patel, D. J. Structural basis of RNA folding and recognition in an AMP-RNA aptamer complex. Nature 382, 183-186 (1996).
79. Soukup, G. A. & Breaker, R. R. Relationship between internucleotide linkage geometry and the stability of RNA. RNA 5, 1308-1325 (1999).
80. Tang, J. & Breaker, R. R. Rational design of allosteric ribozymes. Chem. Biol. 4, 453-459 (1997).
81. Breaker, R. R. Engineered allosteric ribozymes as biosensor components. Curr. Opin. Biotechnol. 13, 31-39 (2002).
82. Silverman, S. K. Rube Goldberg goes (ribo)nuclear? Molecular switches and sensors made from RNA. RNA 9, 377-383 (2003).
83. Seetharaman, S., Zivarts, M., Sudarsan, N. & Breaker, R. R. Immobilized switches for the analysis of complex chemical and biological mixtures. Nature Biotechnol. 19, 336-341 (2001).
84. Hesselberth, J. R., Robertson, M. P., Knudsen, S. M. & Ellington, A. D. Simultaneous detection of diverse analytes with an aptazyme ligase array. Anal. Biochem. 312, 106-112 (2003).
85. Vaish, N. K. et al. Zeptomole detection of a viral nucleic acid using a target-activated ribozymes. RNA 9, 1058-1072 (2003).
86. Kossen, K. et al. High-throughput ribozyme-based assays for detection of viral nucleic acids. Chem. Biol. 11, 807-815 (2004).
87. Srinivasan, J. et al. ADP-specific sensors enable universal assay of protein kinase assay. Chem. Biol. 11, 499-508 (2004).
88. Ferguson, A. et al. A novel strategy for selection of allosteric ribozymes yields Ribo Reporter™ sensors for caffeine and aspartame. Nucleic Acids Res. 32, 1756-1766 (2004).
89. Najafi-Shoushtari, S. H., Mayer, G. & Famulok, M. Sensing complex regulatory networks by conformationally controlled hairpin ribozymes. Nucleic Acids Res. 32, 5212-3219 (2004).
90. Hartig, J. S. et al. Protein-dependent ribozymes report molecular interactions in real time. Nature Biotechnol. 20, 717-722 (2002).
91. Mandal, M. & Breaker, R. R. Gene regulation by riboswitches. Nature Rev. Mol. Cell Biol. 5, 451-463 (2004).
92. Barrick, J. E. et al. New RNA motifs suggest an expanded scope for riboswitches in bacterial genetic control. Proc. Natl Acad. Sci. USA 101, 6421-6426 (2004).
93. Nahvi, A. et al. Genetic control by a metabolite binding mRNA. Chem. Biol. 9, 1043-1049 (2002).
94. Winkler, W., Nahvi, A. & Breaker, R. R. Thiamine derivatives bind messenger RNAs directly to regulate bacterial gene expression. Nature 419, 952-956 (2002).
95. Mandal, M., Boese, B., Barrick, J., E., Winkler, W. C. & Breaker, R. R. Riboswitches control fundamental biochemical pathways in Bacillus subtilis and other bacteria. Cell 113, 577-586 (2003).
96. Mandal, M. & Breaker, R. R. Adenine riboswitches and gene activation by disruption of a transcription terminator. Nature Struct. Mol. Biol. 11, 29-35 (2004).
97. Johansen, L. E., Nygaard, P., Lassen, C., Agerso, Y. & Saxild, H. H. Definition of a second Bacillus subtilis pur regulon comprising the pur and xpt-pbuX operons plus pbuG, nupG (yxjA) and pbuE (ydhL). J. Bacteriol. 185, 5200-5209 (2003).
98. Werstuck, G. & Green, M. R. Controlling gene expression in living cells through small molecule-RNA interactions. Science 282, 296-298 (1998).
99. Grate, D. & Wilson, C. Inducible regulation of the S. cerevisiae cell cycle mediated by an RNA aptamer-ligand complex. Bioorg. Med. Chem. 9, 2565-2570 (2001).
100. Harvey, I., Garneau, P. & Pelletier, J. Inhibition of translation by RNA-small molecule interactions. RNA 8, 452-463 (2002).
101. Suess, B. et al. Conditional gene expression by controlling translation with tetracycline-binding aptamers. Nucleic Acids Res. 31, 1853-1858 (2003).
102. Hanson, S., Berthelot, K., Fink, B., McCarthy, J. E. G. & Suess, B. Tetracycline-aptamer-mediated translational regulation in yeast. Mol. Microbiol. 49, 1627-1637 (2003).
103. Suess, B., Fink, B., Berens, C., Stenz, R. & Hillen, W. A theophylline responsive riboswitch based on helix slipping controls gene expression in vivo. Nucleic Acids Res. 32, 1610-1614 (2004).
104. Sudarsan, N., Barrick, J. E. & Breaker, R. R. Metabolite-binding RNA domains are present in the genes of eukaryotes. RNA 9, 644-647 (2003).
105. Sudarsan, N., Wickiser, J. K., Nakamura, S., Ebert, M. S. & Breaker, R. R. An mRNA structure in bacteria that controls gene expression by binding lysine. Genes Dev. 17, 2688-2697 (2003).
106. Winkler, W. C., Nahvi, A., Roth, A., Collins, J. A. & Breaker, R. R. Control of gene expression by a natural metabolite-responsive ribozyme. Nature 428, 281-286 (2004).
107. Kawasaki, H. & Taira, K. Identification of genes by hybrid ribozymes that couple cleavage activity with the unwinding activity of an endogenous RNA helicase. EMBO Rep. 3, 443-450 (2002).
108. Rhoades, K. & Wong-Staal, F. Inverse Genomics™ as a powerful tool to identify novel targets for the treatment of neurodegenerative diseases. Mech. Age. Dev. 124, 125-132 (2003).
109. Gruenert, D. C. et al. Sequence-specific modification of genomic DNA by small DNA fragments. J. Clin. Invest. 112, 637-641 (2003).
110. Walther, W. & Stein, U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 60, 249-271 (2000).
111. Kuan, J. Y. & Glazer, P. M. Targeted gene modification using triplex-forming oligonucleotides. Methods Mol. Biol. 262, 173-194 (2004).
112. Long, M. B., Jones, J. P., Sullenger, B. A. & Byun, J. Ribozyme-mediated revision of RNA and DNA. J. Clin. Invest. 112, 312-318 (2003).
113. Garcia-Blanco, M. A., Baraniak, A. P. & Lasda, E. L. Alternative splicing in disease and therapy. Nature Biotechnol. 22, 535-546 (2004).
114. Gusarov, I. & Nudler, E. The mechanism of intrinsic transcription termination. Mol. Cell 3, 495-504 (1999).
115. Yarnell, W. S. & Roberts, J. W. Mechanism of intrinsic transcription termination and antitermination. Science 284, 611-615 (1999).